Genmab (GMAB) announces that Orbis Investment Management has informed the company that through shares, as of May 8, it controlled the voting rights to 3,166,357 shares in Genmab, which amounts to 5.08% of the share capital.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Discloses Orbis as 5.08% Major Shareholder
- Yaron Werber Reiterates Hold on Genmab, Citing Strong Execution but 2026‑Weighted Catalyst Risk Profile
- Genmab Terminates Early-Stage GEN1057 Cancer Trial: What Investors Should Watch Next
- Genmab Halts Early-Stage GEN1286 Cancer Trial: What Investors Should Know
- Genmab price target lowered to $33 from $34 at Morgan Stanley